Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAL PHARMA LTD. - 524824 - Intimation On Dispute Resolution Mechanism.

 We would like to inform the exchanges that our Company through its STA has completed the activity of sending email / SMS's to all the physical shareholders whose email / contact number's are registered with the Company , in compliance with the SEBI Circular # SEBI/HO/OIAE/2023/03394 dated January 27, 2023 regarding availability of Dispute resolution mechanism at Stock Exchanges against listed companies / Registrar to an Issue and Share Transfer Agents. Our Share transfer agents M/s.TSR consultants Pvt Ltd has confirmed the completion of the activity of communicating with our shareholders on 10.02.2022 and also has submitted the action taken report in specified format to SEBI, on 18.02.2023.
21-02-2023
Bigul

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Meeting Updates

 Sub : Revised Consolidated Financial Results. Ref: Regulation 30 of SEBI(LODR) Regulations, 2015. With reference to the above, In continuation of our submissions to the exchange on 06.02.2023 with respect to unaudited stand alone and consolidated financial results of the Company for the quarter ended 31.12.2022, we are now submitting to the exchanges revised consolidated financial results of the Company for the quarter and nine months ended 31.12.2022. In the consolidated financial results submitted on 06.02.2023, figures for the 6 months ended 30.09.2022 was furnished as corresponding figures for previous quarter instead of furnishing figures for nine months ended 31.12.2021 as corresponding figures for previous year. We request you to take the revised consolidated financial results on record.
14-02-2023
Bigul

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 We are submitting the attached press release and investor presentation on the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022, announced by us on 06.02.2022.
08-02-2023
Bigul

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 We are submitting to the exchange newspaper advertisements of abridged Un-audited financial results of the Company for the quarter ended 31/12/2022 announced by the Company on 06.02.2023 and published in Financial Express (English) and Sanjay vani (Kannada), on 07th February 2023.
07-02-2023
Bigul

BAL PHARMA LTD. - 524824 - Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2022.

 Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022. A copy of the standalone and consolidated financial results together with the limited review reports issued by the statutory auditors of the Company with un modified opinion, is enclosed. The Board meeting commenced at 4.30 p.m and concluded at 6.20 p.m on 06.02.2023.
06-02-2023
Bigul

BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting

 Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022. A copy of the standalone and consolidated financial results together with the limited review reports issued by the statutory auditors of the Company with un modified opinion, is enclosed. 2.Appointed Mr.Bharath Bhushan D.V as Chief Financial Officer of the Company w.e.f 06.02.2023. A brief on the candidature of Mr.Bhartha Bhushan is enclosed as Annexure to this letter. The Board meeting commenced at 4.30 p.m and concluded at 6.20 p.m on 06.02.2023.
06-02-2023
Bigul

BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 31.12.2022.

 BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2023 ,inter alia, to consider and approve Unaudited financial results of the Company for the quarter ended 31.12.2022. Further, pursuant to amended provisions of SEBI (Prohibition of Insider Trading Regulations),2015 and as per the provisions of Code of Conduct of the Company, the trading window for dealing in securities of the Company by its designated persons/employees and their immediate relatives was closed from 01.01.2023 up to 08.02.2023 i.e 48 hours after declaration of financial results of the Company.
27-01-2023
Bigul

BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 We are submitting to the exchange intimation received from our R&T agents i.e TSR Consultants Pvt Ltd, Mumbai, regarding notice for loss of share certificates by one of our share holder.
23-01-2023
Bigul

BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Confirmation under Regulation 74(5) of SEBI (DP) Regulations, for the quarter ended 31.12.2022.
03-01-2023
Bigul

BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 We are submitting to the exchange intimation received from our R&T agents i.e TSR Consultants Pvt Ltd, Mumbai, regarding loss/reissue of duplicate share certificates by/to one of our shareholder
29-12-2022
Next Page
Close

Let's Open Free Demat Account